Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. The treatment consisted of two cycles of immunotherapy before ...
TipRanks on MSN
Almirall advances LAD603 phase 2 alopecia trial, adding optionality to its dermatology pipeline
Almirall SA ($GB:0O9B) announced an update on their ongoing clinical study. Study Overview: Almirall S.A. is running a phase 2 trial called “A ...
TipRanks on MSN
Eli Lilly’s phase 2 study on imlunestrant: A potential game-changer in breast cancer treatment
Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 2 ...
Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease. The study ...
Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints ...
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...
Ipsen’s oral small molecule has failed to reduce the progression of a genetic disease that gradually turns tendons and ...
ALISCATM-Breast1 study evaluates alisertib in HR-positive, HER2-negative metastatic breast cancer with 150 patients across three dosage groups. Alisertib, an Aurora A kinase inhibitor, is combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback